Could metabo-oncology be the treatment modality of the future?
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
List view / Grid view
Articles
Could downregulating the Drp1 protein prevent Alzheimer’s progression?
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.
Preventing stem cells from transforming into pre-leukaemia stem cells
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
AI advancing drug discovery: the future is multi-cellular studies
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
What is new in the world of imaging?
In this article, Drug Target Review’s Hannah Balfour discusses three of the latest developments in imaging for disease research and drug development.
A novel CAR T-cell therapy to treat lymphomas
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
CRISPR: three new developments in the world of gene editing
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
A single approach to creating effective cancer and autoimmune disease therapeutics
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
How data science is driving genomics in the pharmaceutical industry
In this article, Ramya Sriram describes how data science is driving innovations in medical biotechnology and genomics.
COVID-19 drug development based on boosting immunity
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
A computational effort to deciphering putative COVID-19 3C-like protease binders
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
Unlocking the power of the microbiome in life sciences R&D
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
Human 3D cell-based systems to research gout: drug discovery for a neglected disease
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
RNA sequencing provides insights into why every SARS-CoV-2 infection is different
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
The Editors’ views: Drug Target Review’s 2020 round-up
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.